Abstract 4737
Background
Malignant ependymomas are one of the main types of glioma that have high morbidity and mortality. The objective of this study was to construct, validate and calibrate novel nomograms for the survival of ME patients.
Methods
We utilized the Surveillance, Epidemiology, and End Results database (SEER) to retrieve patients with ME. We excluded patients with an unknown diagnosis, no follow up or with autopsy report only. Moreover, we utilized penalized regression models (PRM) by using “hdnom” package in R with the highest AUC and the most stable calibrations to build nomograms for overall (OS) and cancer-specific survival (CSS).
Results
Data of 3435 patients were retrieved and analyzed. We developed 18 PRM and chose Snet and SCAD for OS and CSS. These two models selected age, sex, year of diagnosis, marital status, site, race, type, surgery, radiation, and chemotherapy for the nomograms to be built. Our nomograms had stable calibrations with adequate to good accuracy AUC of 0.70 to 0.76 for the OS nomogram and AUC of 0.75 to 0.78 for the CSS nomogram.
Conclusions
In this population-based study, we developed nomograms that can better help physicians predict the prognosis and survival of ME patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sherief Ghozy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract